About BerGen Bio

Sponsor retains sole responsibility for content.

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinas...

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create new therapeutic options for cancer patients. BerGenBio’s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with blockbuster potential: Acute myeloid leukaemia (AML); Advanced non-small-cell lung cancer (NSCLC); Triple negative breast cancer (TNBC) The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules. BerGenBio intends to develop its drug candidates itself and through strategic partnerships in multiple indications, and retains all options for the future commercialization of its products.

Contact BerGen Bio

Phone Number
+47 559 61 159

More About BerGen Bio

Therapeutic Areas
  • Oncology
Technologies
  • Drug delivery
Company Type
  • Pharmaceutical
State of Ownership
  • Private
Sponsorship Group
  • Networker
Go to the profile of Andrew Marshall

Andrew Marshall

Chief Editor, Nature Biotechnology, Nature Publishing Group

Go to the profile of Christine Borowski

Christine Borowski

Chief Editor, Nature Medicine, Nature Publishing Group

Go to the profile of Claire Thompson

Claire Thompson

Global Manager, Business Development, Nature Publishing Group

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Publishing Group

Go to the profile of Peter Kirkpatrick

Peter Kirkpatrick

Chief Editor, Nature Reviews Drug Discovery, Nature Publishing Group

Go to the profile of Samia Burridge

Samia Burridge

Business Development Manager, Global Sponsorship, Nature Research Group

Go to the profile of Veronica Zacatenco

Veronica Zacatenco

Business Development Executive, Nature Publishing Group

Go to the profile of Georgia Francis

Georgia Francis

Editorial Assistant, BioPharm Dealmakers, Nature Publishing Group

Go to the profile of Carmen Ramirez

Carmen Ramirez

Sales Account Executive, Springer Nature